Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Heart failure (HF) frequently coexists with conditions associated with glucose insufficiency, such as insulin resistance and type 2 diabetes mellitus (T2DM), and patients with T2DM have a significantly high incidence of HF. These two closely related diseases cannot be separated on the basis of their treatment. Some antidiabetic drugs failed to improve cardiac outcomes in T2DM patients, despite lowering glucose levels sufficiently. This may be, at least in part, due to a lack of understanding of cardiac insulin resistance. Basic investigations have revealed the significant contribution of cardiac insulin resistance to the pathogenesis and progression of HF; however, there is no clinical evidence of the definition or treatment of cardiac insulin resistance. Mitochondrial dynamics play an important role in cardiac insulin resistance and HF because they maintain cellular homeostasis through energy production, cell survival, and cell proliferation. The innovation of diagnostic tools and/or treatment targeting mitochondrial dynamics is assumed to improve not only the insulin sensitivity of the myocardium and cardiac metabolism, but also the cardiac contraction function. In this review, we summarized the current knowledge on the correlation between cardiac insulin resistance and progression of HF, and discussed the role of mitochondrial dynamics on the pathogenesis of cardiac insulin resistance and HF. We further discuss the possibility of mitochondria-targeted intervention to improve cardiac metabolism and HF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Mitochondrial Fission, Fusion, and Stress
Youle, R. J., & van der Bliek, A. M. (2012) · Science · doi:10.1126/science.1219855 · Cited by 3,674 · cited 1×
“Mitochondrial fusion, which is regulated by mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), and optic atrophy-1 (OPA1), supports the inter-organellar exchange of proteins, substrates, and mitochondrial DNA to enhance the stability of mitochondria [61].”
BackgroundBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193 · cited 1×
“In patients with insulin resistance and T2DM, the reduced mitochondrial OXPHOS—due to mitochondrial dysfunction—promotes excess intracellular lipid metabolite accumulation (such as fatty acyl CoAs and diacylglycerol) in the skeletal muscle [58].”
BackgroundReactive Oxygen Species (Ros-Induced) Ros Release
Zorov, D. B., Filburn, C. R., Klotz, L.-O., Zweier, J. L., & Sollott, S. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1001 · Cited by 1,412
Otera, H., Wang, C., Cleland, M. M., Setoguchi, K., Yokota, S., Youle, R. J., & Mihara, K. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201007152 · Cited by 1,110 · cited 2×
“Abbreviations T2DM Type 2 diabetes mellitus HF Heart failure ATP Adenosine triphosphate FDG-PET 18F-2-deoxyglucose positron emission tomography HFrEF HF with a reduced ejection fraction HFpEF HF with a preserved ejection fraction HFmrEF HF with a mid-range ejection fraction mPTP Mitochondrial permeability transition p…”
BackgroundSeferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708 · cited 5×
“In addition, higher HbA1c levels in patients with HF is associated with higher mortality and cardiovascular hospitalization [6].”
BackgroundInfluentialMacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · cited 1×
“T2DM also increased the all-cause mortality in patients with HF and readmission with HF [16,17].”
BackgroundCardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612 · cited 1×
“Previous investigations showed increased myocardium lipid accumulation in T2DM patients by cardiac biopsy [43] and cardiac magnetic resonance imaging (MRI) [44], and the accumulation of lipid metabolites such as triacylglycerol, ceramide, and diacylglycerol—which can induce further metabolic deficiency and/or apoptosi…”
BackgroundCongestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Hillier, T. A., Erbey, J. R., & Brown, J. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1614 · Cited by 600
Rutter, M. K., Parise, H., Benjamin, E. J., Levy, D., Larson, M. G., Meigs, J. B., Nesto, R. W., Wilson, P. W. F., & Vasan, R. S. (2003) · Circulation · doi:10.1161/01.cir.0000045671.62860.98 · Cited by 511
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002560 · Cited by 359
Boudina, S., Bugger, H., Sena, S., O'Neill, B. T., Zaha, V. G., Ilkun, O., Wright, J. J., Mazumder, P. K., Palfreyman, E., Tidwell, T. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.792101 · Cited by 301 · cited 1×
“On the other hand, chronic oxidative stress is known to play the most crucial role for the pathogenesis of insulin resistance [70].”
BackgroundSuskin, N. (2000) · European Heart Journal · doi:10.1053/euhj.1999.2043 · Cited by 271 · cited 1×
“The comorbidity of patients with HF and T2DM have been reported to worsen HF symptoms than those without T2DM, despite having similar ejection fractions as shown by echocardiograms [15,16].”
BackgroundUdell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254 · cited 2×
“Although insulin resistance and T2DM are strong risk factors for HF, intensive glycemic control using several types of anti-diabetes drugs is known to increase the risk of hospitalization for HF [2].”
BackgroundHeart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp604 · Cited by 234 · cited 3×
“Treating the impaired insulin sensitivity seems to be effective against both T2DM and HF; however, the outcome differs depending on the type of insulin-sensitizing agent [20,21].”
BackgroundGerstein, H. C. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1699 · Cited by 217
Role of mitochondrial dynamics proteins in the pathophysiology of obesity and type 2 diabetes
Zorzano, A., Liesa, M., & Palacín, M. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.02.004 · Cited by 209
Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
Shah, D. D., Fonarow, G. C., & Horwich, T. B. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.10.022 · Cited by 100 · cited 2×
“In contrast to PPAR-χ agonists, another insulin-sensitizing agent, metformin, has been recommended as a first-line treatment for patients with T2DM who have cardiovascular risks [25,26].”
BackgroundFunctional class in patients with heart failure is associated with the development of diabetes
Tenenbaum, A., Motro, M., Fisman, E. Z., Leor, J., Freimark, D., Boyko, V., Mandelzweig, L., Adler, Y., Sherer, Y., & Behar, S. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01530-9 · Cited by 99 · cited 1×
“Previous clinical trials clearly revealed that the higher the severity of HF, as indicated by the New York Heart Association class, the higher the risk of T2DM development [10,11].”
ResultPazin-Filho, A., Kottgen, A., Bertoni, A. G., Russell, S. D., Selvin, E., Rosamond, W. D., & Coresh, J. (2008) · Diabetologia · doi:10.1007/s00125-008-1164-z · Cited by 92
Dauriz, M., Targher, G., Temporelli, P. L., Lucci, D., Gonzini, L., Nicolosi, G. L., Marchioli, R., Tognoni, G., Latini, R., Cosmi, F., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005156 · Cited by 70 · cited 1×
“In addition, the GISSI (gruppo Italiano per lo studio della sopravvivenza nell’infarto miocardico; Italian group for the study of the survival of Myocardial Infarction)-HF study indicated that a higher HbA1c was an independent predictor of the composite outcome of mortality and cardiovascular hospitalization [19].”
BackgroundAssociation of heart failure severity with risk of diabetes: a Danish nationwide cohort study
Demant, M. N., Gislason, G. H., Køber, L., Vaag, A., Torp-Pedersen, C., & Andersson, C. (2014) · Diabetologia · doi:10.1007/s00125-014-3259-z · Cited by 45
Cited by
PINK1: The guard of mitochondria
Wang, N., Zhu, P., Huang, R., Wang, C., Sun, L., Lan, B., He, Y., Zhao, H., & Gao, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118247 · Cited by 107
Sakamoto, A., Saotome, M., Iguchi, K., & Maekawa, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164025 · Cited by 73
“Alteration of energetic substrate utilization in myocardium and modification of its intra-cellular signaling pathway also play important roles for the pathogenesis and progression of HF [81].”
BackgroundSelf-citationThe role of Asprosin in patients with dilated cardiomyopathy
Wen, M.-S., Wang, C.-Y., Yeh, J.-K., Chen, C.-C., Tsai, M.-L., Ho, M.-Y., Hung, K.-C., & Hsieh, I.-C. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01680-1 · Cited by 57
“The bioenergetics impairment in the failing heart is reflected by underlying mitochondrial abnormalities, such as impaired electron transport chain activity [12], increased formation of reactive oxygen species [13], shifted metabolic substrate utilization [14, 15], and altered ion homeostasis [16].”
Background
Metadata
- Authors
- Saotome, M., Ikoma, T., Hasan, P., & Maekawa, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-07-20
- Volume
- 20
- Issue
- 14
- Pages
- 3552
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2964282047
- Cited by
- 68
- References
- 26
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.